VIRGINIA COMMONWEALTH UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 10K

Market Cap: -

Website: http://www.vcu.edu

Clinical Trials

The Effect of Brain Anatomy on the Efficacy of Brain Stimulation Therapy

Not Applicable

Completed

Conditions: Healthy

Interventions: Device: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle
Device: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle

First Posted Date: 2020-10-14

Last Posted Date: 2024-05-03

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 12

Registration Number: NCT04586387

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease

Not Applicable

Terminated

Conditions: Parkinson Disease

Interventions: Device: Robotic-assist gait training device

First Posted Date: 2020-10-14

Last Posted Date: 2024-02-28

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 8

Registration Number: NCT04587193

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Improving Adherence to Home Blood Pressure Monitoring With Pharmacist Support

Not Applicable

Terminated

Conditions: Hypertension

Interventions: Behavioral: Weekly check-in

First Posted Date: 2020-10-06

Last Posted Date: 2021-01-15

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 1

Registration Number: NCT04577131

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Phase 1

Withdrawn

Conditions: Refractory Small Cell Lung Carcinoma
Relapsed Small Cell Lung Cancer

Interventions: Drug: Venetoclax 400
Drug: Venetoclax 600
Drug: Venetoclax 50 MG
Drug: Venetoclax 100 MG
Drug: Venetoclax 200 MG
Drug: Irinotecan 60 mg/m2
Drug: Venetoclax (RP2D)

First Posted Date: 2020-09-10

Last Posted Date: 2021-03-03

Lead Sponsor: Virginia Commonwealth University

Registration Number: NCT04543916

Reducing Error in ER Settings Through Attention Restoration Theory

Not Applicable

Withdrawn

Conditions: Attention Fatigue, Attention Restoration

Interventions: Behavioral: Nature slides
Behavioral: Urban slides

First Posted Date: 2020-08-27

Last Posted Date: 2021-04-23

Lead Sponsor: Virginia Commonwealth University

Registration Number: NCT04528862

Virginia Opioid Treatment-Emergency Department

Phase 3

Withdrawn

Conditions: Opioid Use Disorder

Interventions: Drug: SUBLOCADE

First Posted Date: 2020-08-24

Last Posted Date: 2021-02-12

Lead Sponsor: Virginia Commonwealth University

Registration Number: NCT04523792

The Impact of Oral Ethanol and Vaped Ethanol on the Evaluation of Impairment

Not Applicable

Completed

Conditions: Electronic Cigarette Use

Interventions: Other: Beverage with ethanol and E-cigarette liquid with ethanol
Other: Beverage with ethanol and E-cigarette liquid without ethanol
Other: Beverage without ethanol and E-cigarette liquid with ethanol
Other: Beverage without ethanol and E-cigarette liquid without ethanol

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-02

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 7

Registration Number: NCT04522973

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Mindfulness in the OR

Not Applicable

Recruiting

Conditions: Performance at Work

Interventions: Behavioral: Mindfulness
Behavioral: Video

First Posted Date: 2020-08-17

Last Posted Date: 2024-10-03

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 82

Registration Number: NCT04515667

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Phase 1

Completed

Conditions: Alcohol Disorders

Interventions: Drug: Perampanel Tablet
Drug: Disulfiram

First Posted Date: 2020-08-06

Last Posted Date: 2022-10-07

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 4

Registration Number: NCT04502589

Locations: 🇺🇸
Virginia Commonwealth University Inst. for Drug and Alcohol Studies, Richmond, Virginia, United States

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Ovarian Cancer

Interventions: Drug: Neratinib 160 mg
Drug: Niraparib at RP2D
Drug: Neratinib 240 mg
Drug: Neratinib 200 mg
Drug: Niraparib 200 mg
Drug: Niraparib 100 mg
Drug: Niraparib 300 mg
Drug: Neratinib at RP2D

First Posted Date: 2020-08-06

Last Posted Date: 2024-10-29

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 45

Registration Number: NCT04502602

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy